Table 1.
Demographics and clinical characteristics in PD and MSA patients
|
MSA n = 143 |
PD n = 198 |
P value MSA/PD |
MSA‐P n = 95 |
MSA‐C n = 48 |
P valuea
MSA‐P/C |
P valueb
MSA‐P/C |
|
|---|---|---|---|---|---|---|---|
| Demographic data | |||||||
| Age | 61.26 ± 6.93 | 61.78 ± 7.65 | 0.371 | 61.79 ± 6.80 | 60.21 ± 7.13 | 0.199 | |
| Gender (Male/Female) | 55.2% (79/64) | 57.1% (113/85) | 0.737 | 57.9% (55/40) | 50% (24/24) | 0.370 | |
| Disease duration | 3.54 ± 1.96 | 3.42 ± 1.35 | 0.921 | 3.86 ± 1.91 | 2.90 ± 1.92 | 0.002 | |
| Education levelc | 33/81/29 | 32/103/63 | 0.039 | 23/51/21 | 10/30/8 | 0.419 | |
| LEDD (mg/day) | 487.68 ± 383.67 | 282.80 ± 254.35 | 0.000 | 627.82 ± 367.35 | 210.31 ± 237.88 | 0.000 | 0.000 |
| Toxic exposure (+/−) | 18.9% (27/116) | 28.3% (56/142) | 0.062 | 21.1% (20/75) | 14.6% (7/41) | 0.351 | 0.390 |
| Family history (+/−) | 4.2% (6/137) | 18.2% (36/162) | 0.000 | 6.3% (6/89) | 0% (0/48) | 0.179 | 0.056 |
| Clinical feature | |||||||
| HY stage | 3.51 ± 1.19 | 1.55 ± 0.55 | 0.000 | 3.60 ± 1.19 | 3.33 ± 1.19 | 0.202 | 0.819 |
| Pyramid sign (+/−) | 51.0% (73/70) | / | / | 55.8% (53/42) | 41.7% (20/28) | 0.111 | 0.209 |
| OH (+/−) | 30.1% (43/100) | / | / | 28.4% (27/68) | 33.3% (16/32) | 0.545 | 0.526 |
| UMSARS I | 19.80 ± 7.97 | / | / | 21.23 ± 8.23 | 16.96 ± 6.65 | 0.002 | 0.026 |
| UMSARS II | 22.58 ± 10.51 | / | / | 25.25 ± 9.92 | 17.29 ± 9.68 | 0.000 | 0.000 |
| UMSARS IV | 2.59 ± 1.32 | / | / | 2.82 ± 1.31 | 2.13 ± 1.21 | 0.002 | 0.019 |
| RBDSQ | 4.07 ± 2.79 | 3.65 ± 3.27 | 0.077 | 3.80 ± 2.88 | 4.60 ± 2.56 | 0.094 | 0.076 |
| RBDSQ (+/−) | 46.9% (67/76) | 35.9% (71/127) | 0.041 | 41.1% (39/56) | 58.3% (28/20) | 0.051 | 0.028 |
| SS‐16 | 7.92 ± 0.33 | 7.58 ± 0.27 | 0.450 | 6.94 ± 3.91 | 8.50 ± 3.79 | 0.026 | 0.021 |
| SS‐16 (+/−) | 46.9% (67/76) | 48.5% (96/102) | 0.766 | 53.7% (51/44) | 33.3% (16/32) | 0.021 | 0.023 |
| HAMD‐17 | 9.98 ± 5.19 | 5.92 ± 4.76 | 0.000 | 11.10 ± 5.17 | 7.85 ± 4.58 | 0.000 | 0.001 |
| HAMD‐17 (+/−) | 60.1% (86/57) | 29.8% (59/139) | 0.000 | 67.4% (64/31) | 45.8% (22/26) | 0.013 | 0.023 |
| HAMA | 11.01 ± 5.47 | 7.89 ± 6.30 | 0.000 | 12.02 ± 5.48 | 9.19 ± 5.00 | 0.004 | 0.013 |
| HAMA (+/−) | 75.5% (108/35) | 60.1% (120/78) | 0.004 | 77.9% (74/21) | 70.8% (34/14) | 0.354 | 0.753 |
| MMSE | 25.12 ± 4.57 | 27.09 ± 3.06 | 0.000 | 24.58 ± 5.21 | 26.10 ± 2.85 | 0.320 | 0.044 |
| MMSE (+/−) | 16.1% (23/120) | 5.6% (11/187) | 0.001 | 22.1% (21/74) | 4.2% (2/46) | 0.006 | 0.005 |
| SCOPA‐AUT | 21.26 ± 9.41 | 10.07 ± 7.93 | 0.000 | 22.41 ± 9.49 | 19.02 ± 8.94 | 0.042 | 0.186 |
HAMD‐17: 17‐item Hamilton Rating Scale; HAMA: Hamilton Anxiety Scale; HY stage: Hoehn and Yahr (HY) stage; LEDD: levodopa equivalent daily dosage; MMSE: Mini‐Mental State Examination; MSA: multiple system atrophy; MSA‐C: MSA with prominent cerebellar ataxia; MSA‐P: MSA with predominant parkinsonism; OH: orthostatic hypotension; PD: Parkinson’s disease; RBDSQ: Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA‐AUT: The Scale for Outcomes in PD autonomic dysfunction; SS‐16: 16‐item odor identification test from Sniffin' Sticks; UMSARS: the Unified Multiple System Atrophy Rating Scale.
Means the comparison between MSA‐P and MSA‐C.
Means the comparison between MSA‐P and MSA‐C after adjusting disease duration by analyses of covariance (ANCOVA).
Education level (primary school and below/middle and high school/bachelor's degree and above). Bold indicates p ＜ 0.05.